PD-L1 Antikörper

Produktnummer ABIN1106177

Der Maus Monoklonal Anti-PD-L1 Antikörper wurde für FACS validiert. Er ist geeignet, PD-L1 in Proben von Human zu detektieren.

Kurzübersicht für PD-L1 Antikörper (ABIN1106177)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PD-L1 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Klon: MIH3

Produktdetails anti-PD-L1 Antikörper

Spezifität: This antibody reacts with human CD274 antigen.

Aufreinigung: Protein A agarose

Immunogen: Full-length human PD-L1 transfected L cells

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS containing 50 % glycerol, pH 7.2. Contains no preservatives.

Konservierungsmittel: Without preservative

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Store (in aliquots) at -20 °C.

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: CD274 / PDL1

Hintergrund: Programmed death ligand 1 (PD-L1, also known as CD274/B7-H1), a member of B7 family was identified by searching for molecules that share homology with the immunoglobulin V and C domains of B7-1 and B7-2 among the human cDNA expressed sequence tags in the National Center for Biotechnology Information database. PD-L1 is a ligand for programmed death 1 (PD-1) which belongs to the CD28/CTLA4 subfamily. Although in vitro study indicated that the cross-linking of PD-1 by PD-L1 leads to down-regulation of T-cell responses, some studies have shown that T cells stimulated with low levels of anti-CD3 and immobilized PD-L1-Ig were activated, proliferation and production of IFN-γ, GM-CSF and IL-10 from the T cells were enhanced.Synonyms: B7 homolog 1, B7H1, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1, Programmed death ligand 1

Gen-ID: 29126

NCBI Accession: NP_054862

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints